Evidence map›Paper›PMID 28255908›Full record

ArticleMolecular neurobiology2018

NLRP3 Inflammasome Inhibitor Ameliorates Amyloid Pathology in a Mouse Model of Alzheimer's Disease.

Jun Yin, Fanpeng Zhao, Jeremy E Chojnacki, Jacob Fulp, William L Klein, Shijun Zhang, Xiongwei Zhu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular neurobiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 121 papers.

0numbers the graph read from it
0cells of the map it votes in
121citing papers in PubMed
11.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

121 citing papers in PubMed, 221 citations in OpenAlex.

  1. Review
  2. Review
  3. Programmed cell death: a promising management for Alzheimer's disease.Apoptosis : an international journal on programmed cell death · 2026
    Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Beyond Neuroinflammation: Microglia at the Crossroads of Amyloid, Tau, and Neurodegeneration in Alzheimer's Disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Role of NLRP3 Inflammasome in Chronic Pain and Alzheimer's Disease-A Review.Journal of biochemical and molecular toxicology · 2025
    Review
  20. Review

61 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Jun YinDepartment of Pathophysiology, School of Basic Medical Sciences, Wuhan University, Wuhan, Hubei, China.
Fanpeng ZhaoDepartment of Pathology, Case Western Reserve University, Cleveland, OH, USA.
Jeremy E ChojnackiDepartment of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA, 23298, USA.
Jacob FulpDepartment of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA, 23298, USA.
William L KleinDepartment of Neurobiology, Northwestern University, Evanston, IL, USA.
Shijun ZhangDepartment of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA, 23298, USA. szhang2@vcu.edu.
Xiongwei ZhuDepartment of Pathology, Case Western Reserve University, Cleveland, OH, USA. xiongwei.zhu@case.edu.ORCID http://orcid.org/0000-0003-2092-6508
Virginia Commonwealth University · USCase Western Reserve University · USNorthwestern University · USWuhan University · CN

Funding

Molecular Mechanisms Underlying Mitochondrial Dynamics Abnormalities in Alzheimer DiseaseRF1AG049479 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI ZHU, XIONGWEI · 2016 to 2016
$2.6M
Abnormal Mitochondrial Dynamics and Mitochondrial Dysfunction in Alzheimer's DiseR01NS083385 · NINDS · CASE WESTERN RESERVE UNIVERSITY · PI ZHU, XIONGWEI · 2013 to 2017
$2.1M
Novel bivalent multifunctional ligands towards Alzheimer's diseaseR01AG041161 · NIA · VIRGINIA COMMONWEALTH UNIVERSITY · PI ZHANG, SHIJUN · 2012 to 2016
$1.5M
Alzheimer's Association AARG-16-443584Alzheimer's Drug Discovery Foundation 20150601Dr. Robert M. Kohrman Memorial Fund NoneNational Natural Science Foundation of China 81100594NIA NIH HHS R01 AG041161NIA NIH HHS R01AG041161NIA NIH HHS RF1 AG049479NIA NIH HHS RFAG049479NINDS NIH HHS NS083385NINDS NIH HHS R01 NS083385
6 · The paper itself

Abstract

The activation of the NLRP3 inflammasome signaling pathway plays an important role in the neuroinflammation in Alzheimer's disease (AD). In this study, we investigated the effects of JC-124, a rationally designed NLRP3 inflammasome inhibitor, on AD-related deficits in CRND8 APP transgenic mice (TgCRND8). We first demonstrated increased formation and activation of NLRP3 inflammasome in TgCRND8 mice compared to non-transgenic littermate controls, which was inhibited by the treatment with JC-124. Importantly, JC-124 treatment led to decreased levels of Aβ deposition and decreased levels of soluble and insoluble Aβ

Indexed as

Alzheimer DiseaseAmyloidAnimalsDisease Models, AnimalFemaleMaleMiceMice, Inbred C3HMice, Inbred C57BLMice, TransgenicNeuroprotective AgentsNLR Family, Pyrin Domain-Containing 3 ProteinAmyloidNeuroprotective AgentsNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, mouseAlzheimer’s diseaseAmyloid-betaInflammasomeNeuroinflammationNLRP3

Identifiers

PMID28255908
PMCPMC5585057
OpenAlexW2594548297

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.